Related Experiment Videos
Immunization-based scores as independent prognostic predictors in soft tissue sarcoma patients
Shan-Shan Jiang1, Long Jiang2, De-Sheng Weng3
1Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, 510060, China.; Department of Medical oncology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Qingchun Road 79#, Hangzhou, 310003, China.
Journal of Cancer
|April 4, 2017
Summary
The Glasgow Prognostic Score (GPS) effectively predicts outcomes for soft tissue sarcoma (STS) patients. Modified GPS systems (m1GPS, m2GPS) offer superior prognostic accuracy over the traditional GPS (tGPS) for overall survival and progression-free survival.
Area of Science:
- Oncology
- Immunology
- Clinical Research
Background:
- Soft tissue sarcoma (STS) is a complex malignancy requiring accurate prognostic indicators.
- Existing scoring systems for STS prognosis vary in their predictive capabilities.
- Immunization-based scores, like the Glasgow Prognostic Score (GPS), are being investigated for their utility in STS.
Purpose of the Study:
- To compare the prognostic value of different Glasgow Prognostic Score (GPS) systems in patients with soft tissue sarcoma (STS).
- To evaluate the predictive accuracy of traditional GPS (tGPS), modified GPS 1 (m1GPS), and modified GPS 2 (m2GPS) for overall survival (OS) and progression-free survival (PFS).
- To assess the utility of GPS in guiding treatment strategies for metastatic STS.
Main Methods:
- Retrospective analysis of 165 STS patients diagnosed between July 2007 and July 2014.
- Calculation of tGPS, m1GPS, and m2GPS for all patients.
- Correlation of GPS scores with clinicopathological characteristics and survival outcomes (OS and PFS).
Main Results:
- Lower GPS scores (score 0) correlated with better overall survival, while higher scores (score 2) correlated with poorer progression-free survival, irrespective of the scoring system used.
- The modified GPS system 1 (m1GPS) demonstrated the highest accuracy in predicting both OS and PFS.
- In patients with a GPS score of 2, local treatment was associated with a worse prognosis compared to those who did not receive local treatment.
Conclusions:
- The Glasgow Prognostic Score (GPS) serves as a valuable prognostic marker for soft tissue sarcoma (STS) patients.
- Modified GPS systems (m1GPS and m2GPS) exhibit superior prognostic and predictive performance compared to the traditional GPS (tGPS).
- GPS can aid in determining optimal treatment strategies, particularly for STS patients with metastases.